These p53 activating agents act synergistically with each other and with DNA-damaging radiation and chemotherapy in TP53-WT tumors, leading to clinical trials that combine p53 activators and cytotoxic drugs in multiple myeloma, acute myeloid leukemia, and B cell lymphoma. Here, TP53 is linked to acute myeloid leukemia.